首页 正文

Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC)

{{output}}
The authors present a clinical case of a caucasian male patient, 59 years-old, non-smoker, with an advanced non-small cell lung carcinoma (NSCLC), with 3 years of follow-up, received erlotinib for 18 months, after failure of more than one chemotherapy schedule... ...